Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Sunmo succeeds in a setting very similar to Starglo's.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
A new KRAS degrader and PD-1 x Lag3 bispecific have just started phase 1.
Suzhou Zelgen’s DLL3 x DLL3 project looks better than regular T-cell engagers, with caveats.
